By Brajesh Jha, RPH, MSHCA, MBA

Nepal’s pharmaceutical industry is once again asking the government to tighten restrictions on imported medicines. Industry leaders argue that domestic manufacturers are operating at barely 30–40% capacity, several companies are on the verge of closure, and foreign competition, particularly from India, is suffocating local production. (Ratopati, 2026) Their concerns are real. But the solution cannot simply be “ban imports.”

Nepal stands at a critical crossroads. If policymakers overprotect the domestic pharmaceutical sector, consumers may end up paying higher prices for fewer choices. If the government ignores the struggles of local industries, Nepal risks becoming permanently dependent on foreign medicines. The answer lies not in isolation, but in strategic self-reliance.

There is merit in supporting domestic pharmaceutical manufacturing. Medicine is not an ordinary commodity; it is a matter of national security. The COVID-19 pandemic exposed how fragile global supply chains can become during crises. Countries that lacked domestic manufacturing capacity suffered shortages, delays, and dependence on geopolitics. Nepal cannot afford that vulnerability forever.

Local pharmaceutical industries also generate employment, tax revenue, technical expertise, and industrial growth. According to industry representatives, over Rs 40 billion has already been invested in Nepal’s pharmaceutical sector. (Ratopati, 2026) If properly supported, the industry could reduce Nepal’s trade deficit and keep billions of rupees circulating within the domestic economy.

However, the pharmaceutical lobby’s argument becomes problematic when it drifts toward blanket protectionism.

Competition from imports is not automatically unfair competition. Indian pharmaceutical companies operate at larger scales, reducing production costs through economies of scale. Nepali companies understandably struggle to match those prices. But consumers should not be penalized simply because domestic producers are less competitive.

The first responsibility of any healthcare system is affordability and access.

If Nepal abruptly restricts imports of medicines widely used by the public, prices could rise sharply. Patients suffering from chronic diseases, diabetes, hypertension, thyroid disorders, heart disease, cancer, would bear the consequences. For a country where out-of-pocket healthcare spending is already high, even a modest increase in medicine prices could push families deeper into financial distress.

Moreover, domestic manufacturing capacity alone does not guarantee quality or innovation. Nepal’s pharmaceutical industry remains heavily concentrated on generic medicine production and still lacks significant investment in research and development. (Nepali Times, 2026) Many advanced drugs, vaccines, and patented medicines cannot yet be produced locally at sufficient scale or technological sophistication.

This is why the debate must move beyond slogans like “buy Nepali medicines” versus “free imports.”

Instead, Nepal needs a phased industrial strategy.

First, the government should identify medicines where Nepal already has strong production capacity and gradually prioritize domestic procurement in those categories. This approach is smarter than imposing broad import restrictions. If local manufacturers can reliably supply certain antibiotics, painkillers, or essential generics at acceptable quality standards, the state can encourage hospitals and public health institutions to source locally.

Second, policymakers must address the structural disadvantages faced by domestic manufacturers. Industry leaders are correct when they say that importing packaging materials, machinery, and raw ingredients often attracts taxes and procedural hurdles that raise production costs. (Ratopati, 2026) Reducing duties on pharmaceutical equipment, simplifying licensing procedures, subsidizing industrial financing, and supporting technology upgrades would strengthen competitiveness more effectively than import bans.

Third, regulation must become stronger and more transparent.

The government cannot simultaneously promote domestic industry while failing to control illegal, contraband, or unregistered medicines in the market. Reports of unauthorized drug sales and pricing irregularities damage public trust in the pharmaceutical ecosystem as a whole. (Ratopati, 2026) Stronger monitoring by the Department of Drug Administration is essential—not only for imported products, but also for locally produced medicines.

Finally, Nepal must think globally, not defensively. As Nepal graduates from Least Developed Country (LDC) status, stricter intellectual property obligations under international trade agreements will reshape the pharmaceutical landscape. (New Business Age)⁴ Rather than retreat inward, Nepal should invest in partnerships, technology transfer, and foreign collaboration to modernize its pharmaceutical sector. Strategic foreign investment, if properly regulated, could help Nepal build capabilities in vaccine production, biotechnology, and higher-value manufacturing. (Nepali Times)²

The future of Nepal’s pharmaceutical industry should not depend on shutting doors to competition. It should depend on becoming competitive enough that Nepali medicines are chosen because they are trusted, affordable, and high-quality—not because consumers have no alternative.

Protection may offer temporary relief. But long-term resilience will come only through innovation, efficiency, and credibility.

References

Nepali drug manufacturers demand protection against imports. (n.d.). Ratopati | No.1 Nepali News Portal: https://english.ratopati.com/story/64149/pharmaceutical-industry-demands-stricter-controls-on-foreign-drug-imports

Nepal must allow foreign investment in pharmaceuticals. (2021, June 14). Nepali Times. https://nepalitimes.com/nepal-must-allow-foreign-investment-in-pharmaceuticals

RSP Lawmaker Demands Probe into Unauthorized Drug Price Hikes. (n.d.). Ratopati | No.1 Nepali News Portal: https://english.ratopati.com/story/58025/mp-rajiv-khatri-alleges-scam-worth-billions-in-medicine-prices

Testing times for Pharma Industry | New Business Age. Available at: https://newbusinessage.com/news/41966/testing-times-for-pharma-industry/ (Accessed: 26 May 2026).

About the Author

Brajesh Jha is a healthcare operations professional and pharmacist with extensive experience across hospital pharmacy, supply chain management, and healthcare system implementation in Nepal. He currently serves as a System Implementation Coordinator at Pharma Life, where he focuses on optimizing operational workflows, deploying healthcare software systems, and improving efficiency across network pharmacies.

With a background that includes hospital pharmacy practice, academic roles in healthcare management, and entrepreneurial experience as the founder of a community pharmacy during the COVID-19 pandemic, he brings a practical, systems-oriented perspective to healthcare challenges.

He holds a Bachelor of Pharmacy, a Master’s in Health Care Administration, and an MBA, with academic work centered on digital transformation in pharmaceutical supply chains. His work and commentary focus on making healthcare operations more efficient, data-driven, and reliable.